Polysubstituted Benzene EZH2 Inhibitors for Better Metabolic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EZH2 inhibitors fail to effectively inhibit the activity of EZH2, leading to poor pharmacokinetic parameters and metabolic characteristics, which are crucial for drug efficacy in treating EZH2-mediated diseases such as cancer.
Innovation Solution
A novel EZH2 inhibitor compound, represented by formula (I), is developed to inhibit EZH2 activity, with specific substituents that enhance pharmacokinetic characteristics and metabolic stability, allowing for effective treatment of EZH2-mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing EZH2 inhibitors are used, then EZH2 activity is inhibited to some extent, but pharmacokinetic parameters and metabolic characteristics are poor, leading to reduced drug efficacy
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical substituents at specific positions of the benzene ring structure. Different substituents (R1-R8) are varied to optimize pharmacokinetic parameters including metabolic stability, bioavailability, and half-life, while maintaining EZH2 inhibitory activity. This involves changing physical and chemical properties of the molecule to improve its pharmacokinetic profile.
Solution Approach 2:
The patent employs composite material principles by combining multiple substituent groups on the benzene core structure to create a composite molecular architecture. The compound integrates electron-donating, electron-withdrawing, and sterically bulky groups in specific patterns to achieve synergistic effects that improve both metabolic stability and pharmacokinetic properties while preserving target binding affinity.
2Duration of action of moving object
If current EZH2 inhibitors are administered, then some inhibition of EZH2 activity is achieved, but the duration of drug action is insufficient due to poor pharmacokinetic characteristics
Solution Approach 1:
The patent utilizes parameter changes by introducing specific substituent patterns that extend the duration of drug action. This includes adding metabolically stable groups that resist degradation, increasing molecular weight within optimal ranges, and modifying lipophilicity to improve tissue distribution and retention, thereby extending the effective duration of EZH2 inhibition.
3Quantity of substance
If novel compound structures are developed to improve pharmacokinetic properties, then metabolic stability may be enhanced, but the complexity of compound design and synthesis increases
Solution Approach 1:
The patent applies local quality by making targeted modifications at specific positions (R1-R8) of the benzene ring rather than globally redesigning the entire molecule. Each substituent position is optimized independently based on its specific contribution to metabolic stability, allowing systematic improvement of pharmacokinetic properties while maintaining a relatively simple core structure that is easier to synthesize.
Data Source
AI summary
The present invention provides a novel EZH2 inhibitor compound represented by formula (I) and a use of the inhibitor compound in preventing or treating a disease mediated by EZH2.